Drug Profile
Keliximab
Alternative Names: Anti-CD4 monoclonal antibody IDEC-CE9.1; CE9.1; IDEC-CE9.1; PRIMATIZED anti-CD4 antibody IDEC-CE9.1; SB 210396Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator IDEC Pharmaceuticals
- Developer GlaxoSmithKline; IDEC Pharmaceuticals
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action CD4 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Rheumatoid arthritis
Most Recent Events
- 15 May 2001 Discontinued-III for Asthma in USA (Unknown route)
- 15 May 2001 Discontinued-III for Rheumatoid arthritis in USA (Infusion)
- 15 May 2001 Discontinued-Preclinical for Rheumatoid arthritis in Japan (Infusion)